biostudies-literatureUnknown29(24)Oza AM<h4>Purpose</h4>Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation, and cell cycle progression. Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting.<h4>Patients and methods</h4>Sequential phase II studies evaluated single-agent activity of temsirolimus in women with recurrent or metastatic chemotherapy-naive or chemotherapy-treated endometrial cancer. TemsirolimJournal of clinical oncology : official journal of the American Society of Clinical Oncology3278-85https://www.ebi.ac.uk/biostudies/studies/S-EPMC3158598biostudies-literaturePhase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.PMC3158598Ivy POza AMEisenhauer EABiagi JTsao MSKamel-Reid SHoskins PJGhatage PProvencher DMGotlieb WHDancey JEMackay HJMazurka JTonkin KSSederias JElit LfalsePhase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.<h4>Purpose</h4>Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation, and cell cycle progression. Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting.<h4>Patients and methods</h4>Sequential phase II studies evaluated single-agent activity of temsirolimus in women with recurrent or metastatic chemotherapy-naive or chemotherapy-treated endometrial cancer. Temsirolim2011-01-01T00:00:00Z2011 Aug2025-06-01T12:16:45.2Z2019-03-27T00:43:09ZS-EPMC31585982178856410.1200/JCO.2010.34.157810.1200/jco.2010.34.1578